Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation
March 11, 2019 08:30 ET
|
Espero BioPharma
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis...
Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in China
January 24, 2019 11:00 ET
|
Espero BioPharma
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis...
Espero BioPharma Appoints Lee Golden, M.D., as Chief Medical Officer
October 09, 2018 09:00 ET
|
Espero Biopharma
JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs...
Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018
May 30, 2018 09:00 ET
|
Espero Biopharma
JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to...
Espero BioPharma to Present at Biotech Showcase on January 9, 2018
January 03, 2018 08:30 ET
|
Espero Biopharma
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat...
Espero BioPharma Provides Corporate Update and 2018 Objectives
December 12, 2017 08:30 ET
|
Espero Biopharma
- Pivotal Phase 3 trial for tecarfarin under FDA-approved Special Protocol Assessment provides clear regulatory pathway to the $8.5 billion U.S. oral anticoagulant market - JACKSONVILLE, Fla. and...